Search results for "From ACP Internist Weekly"
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://diabetes.acponline.org/archives/2022/10/14/7.htm
14 Oct 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
No additional benefit seen for self-monitored blood glucose with community health worker support
In a small trial, patients with insulin-treated diabetes were randomly assigned to usual care, a lottery incentive for daily self-monitored blood glucose, or the lottery plus support from a community health worker if needed.
https://diabetes.acponline.org/archives/2022/06/10/6.htm
10 Jun 2022
Paternal metformin use associated with major birth defects
A prospective registry-based study in Denmark found that offspring of men who filled one or more prescriptions for metformin during the three months of developing fertilizing sperm were more likely to have a birth defect, while insulin and sulfonylureas were not associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/6.htm
8 Apr 2022
Tailoring diabetes screening by race, ethnicity may lead to earlier diagnosis
Researchers used data from the National Health and Nutrition Examination Survey to determine the body mass index and age thresholds for diabetes screening in major racial/ethnic minority populations.
https://diabetes.acponline.org/archives/2022/05/13/8.htm
13 May 2022
Targeting social needs may help improve type 2 diabetes outcomes, review finds
A systematic review found that HbA1c levels were improved significantly by food supplementation with referral and diabetes support, financial incentives with education and skills training, housing relocation with counseling support, and the integration of nonmedical interventions into medical care.
https://diabetes.acponline.org/archives/2022/07/08/6.htm
8 Jul 2022
Treatment pathways compared for diabetic peripheral neuropathy
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
https://diabetes.acponline.org/archives/2022/09/16/7.htm
16 Sep 2022
New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.
https://diabetes.acponline.org/archives/2021/06/11/7.htm
11 Jun 2021
Kidney failure, CV events lower with canagliflozin than placebo, industry study finds
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
https://diabetes.acponline.org/archives/2019/05/10/10.htm
10 May 2019